Clinical Trial Update: Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD) [Phase 3]

View source ↗

Summary

Phase 3 trial update for TAK-438 10 mg in non-erosive gastroesophageal reflux disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-erosive Gastroesophageal Reflux Disease

Drugs mentioned

• TAK-438 10 mg (TAK-438)

Snippet

Sponsor: Takeda | Conditions: Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-08-02